QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Surowiec, D. Articles by Cicogna, C. E Search for Related Content PubMed PubMed Citation Articles by Surowiec, D. Articles by Cicogna, C. E

INFECTIOUS DISEASES

Past, Present, and Future Therapies for Clostridium difficile-Associated Disease

at time of writing, Pharmacy Practice Resident, Hackensack University Medical Center, Hackensack, NJ; now, Specialty Resident in Infectious Diseases and Clinical Instructor, University of Michigan Health System and College of Pharmacy, Ann Arbor, MI

Arpi G Kuyumjian, PharmD

Clinical Coordinator and Clinical Pharmacy Specialist in Infectious Diseases, Hackensack University Medical Center

Michael A Wynd, PharmD BCPS

Clinical Associate Professor, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ; and Hackensack University Medical Center

Cristina E Cicogna, MD

Clinical Assistant Professor of Medicine, University of Medicine and Dentistry of New Jersey, Newark, NJ; Hospital Epidemiologist, Hackensack University Medical Center

Reprints: Dr. Surowiec, Department of Pharmacy Services and College of Pharmacy, UH B2D301 University Hospital, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, fax 734/936-7027, dsurowiec{at}hotmail.com

OBJECTIVE: To describe and examine the past, present, and potential future treatment options for Clostridium difficile-associated disease (CDAD).

DATA SOURCES: A PubMed search, restricted to English-language articles concerning CDAD, was conducted (1965-October 2006) using the key words Clostridium difficile, diarrhea, vancomycin, metronidazole, immunoglobulin, and recurrence. Additional references were located through review of the bibliographies of cited articles and by visiting www.clinicaltrials.gov.

STUDY SELECTION AND DATA EXTRACTION: Articles related to the clinical manifestations, diagnosis, and treatment of CDAD, as well as articles addressing current issues related to CDAD, were included.

DATA SYNTHESIS: There have been many investigations into CDAD because of the recent increased incidence and morbidity and mortality of the disease. Various studies examining the changing epidemiology and pathogenicity of C. difficile, as well as new therapies for CDAD with agents such as tolevamer and nitazoxanide, are ongoing. In addition, researchers are investigating probiotics and vaccines to evaluate their effectiveness in preventing CDAD and/or preventing recurrences of CDAD. Studies assessing therapies for refractory CDAD are lacking, although case reports have been published citing treatment strategies using vancomycin enemas, intravenous metronidazole, colestipol and cholestyramine, fecal enemas, bowel irrigation, and immunoglobulin. Furthermore, judicious use of antimicrobials, contact precautions, and adequate environmental cleaning are being evaluated in healthcare institutions as methods for controlling and preventing the spread of C. difficile.

CONCLUSIONS: Oral metronidazole is the drug of choice for an initial CDAD episode. Oral vancomycin is an option for patients who cannot take or fail treatment with oral metronidazole. Clinical trials are necessary to define the therapy for initial CDAD that is most appropriate and produces lower recurrence rates compared with oral metronidazole or vancomycin treatment. Moreover, appropriate treatment for patients with multiple recurrences of or refractory CDAD needs to be determined. More studies are also needed assessing prevention of recurrences of CDAD.

Key Words: Clostridium difficile-associated disease, metronidazole, vancomycin

Published Online, December 5, 2006. www.theannals.com, DOI 10.1345/aph.1H332

This article has been cited by other articles:

				K. W Garey, M. Salazar, D. Shah, R. Rodrigue, and H. L DuPont Rifamycin Antibiotics for Treatment of Clostridium difficile-Associated Diarrhea Ann. Pharmacother., June 1, 2008; 42(6): 827 - 835. [Abstract] [Full Text] [PDF]

				C. R. Emerson Clostridium difficile Associated Diarrhea, an Emerging Epidemic: Therapeutic Options Journal of Pharmacy Practice, August 1, 2007; 20(4): 347 - 353. [Abstract] [PDF]

				M. Segarra-Newnham Probiotics for Clostridium difficile-Associated Diarrhea: Focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii Ann. Pharmacother., July 1, 2007; 41(7): 1212 - 1221. [Abstract] [Full Text] [PDF]